CD38 and hematologic disorder: Hematologic malignancy patients who received treatment with CART (P < 0.0001), Mab-CD20 (P < 0.0001), BKI (P < 0.0001), BCL2i (P < 0.0001), and JAKi (P = 0.0238) were associated with lower seroconversion rates compared to untreated patients, while those who received chemotherapy, Mab-CD38, IMiD, PI, HSCT, and TKI had no significant response rates compared to the untreated group.